Log in

NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Forecast & News

$84.50
+2.01 (+2.44 %)
(As of 04/1/2020 03:22 AM ET)
Today's Range
$80.68
Now: $84.50
$85.57
50-Day Range
$71.37
MA: $86.25
$96.85
52-Week Range
$62.88
Now: $84.50
$97.10
Volume2.38 million shs
Average Volume1.58 million shs
Market Capitalization$15.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
BioMarin Pharmaceutical logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.68 per share
Book Value$17.38 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Employees3,001
Market Cap$15.20 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.


BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BMRN stock has decreased by 2.8% and is now trading at $84.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioMarin Pharmaceutical.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for BioMarin Pharmaceutical.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Wednesday, February, 26th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.07. The biotechnology company earned $454.44 million during the quarter, compared to analysts' expectations of $461.88 million. BioMarin Pharmaceutical had a negative net margin of 1.40% and a positive return on equity of 0.81%. View BioMarin Pharmaceutical's earnings history.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.95-2.05 billion, compared to the consensus revenue estimate of $1.95 billion.

What price target have analysts set for BMRN?

18 analysts have issued 1 year target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $164.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $113.11 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price. View analysts' price targets for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs — Vimizim and Kuvan — continue to do well, driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is also progressing well. The company filed regulatory applications for Valrox in late 2019 and targets the same for vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry in the past one year.<" (1/15/2020)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News coverage about BMRN stock has trended very negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBioMarin Pharmaceutical.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a increase in short interest in March. As of March 13th, there was short interest totaling 9,938,200 shares, an increase of 9.6% from the February 27th total of 9,070,000 shares. Based on an average daily volume of 1,818,000 shares, the short-interest ratio is presently 5.5 days. Approximately 5.6% of the company's stock are sold short. View BioMarin Pharmaceutical's Current Options Chain.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $84.50.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $15.20 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe. View additional information about BioMarin Pharmaceutical.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is http://www.bmrn.com/.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,412 (Vote Outperform)
Underperform Votes:  853 (Vote Underperform)
Total Votes:  2,265
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Circuit Breakers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel